Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kangmei Pharmaceutical CoSHSE:600518 48 Days Payable is 260.80 as of Mar. 2026, which is 27% above its 10-year median of 205.48. GuruFocus rates SHSE:600518 with a GF Score™ of 48/100 and a GF Value™ of ¥1.46 (Fairly Valued). The stock has 2 warning signs investors should review. Among 926 Drug Manufacturers companies, Kangmei Pharmaceutical Co ranks better than 87.04% on this metric.
The historical rank and industry rank for Kangmei Pharmaceutical Co's Days Payable or its related term are showing as below:
SHSE:600518'
s Days Payable Range Over the Past 10 Years
Min: 40.93 Med: 205.48 Max: 302.42
Current: 227.56
During the past 13 years, Kangmei Pharmaceutical Co's highest Days Payable was 302.42. The lowest was 40.93. And the median was 205.48.
SHSE:600518's Days Payable is ranked better than 87.04% of 926
companies
in the Drug Manufacturers industry
Industry Median: 90.22
vs SHSE:600518: 227.56
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Kangmei Pharmaceutical Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kangmei Pharmaceutical Co Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kangmei Pharmaceutical Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Kangmei Pharmaceutical Co's Days Payable falls into.
Kangmei Pharmaceutical Co Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Kangmei Pharmaceutical Co's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kangmei Pharmaceutical Co (SHSE:600518) has a Days Payable of 260.80 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Kangmei Pharmaceutical Co and its competitors. This is 27% above median its historical median of 205.48. Over the past decade, Kangmei Pharmaceutical Co's Days Payable has ranged from 40.93 to 302.42. According to the industry distribution chart, Kangmei Pharmaceutical Co ranks #120 out of 926 companies in the Drug Manufacturers industry, placing it in the top 13%.
Is Kangmei Pharmaceutical Co's Days Payable too high?
Kangmei Pharmaceutical Co's current Days Payable of 260.80 is 27% above median its 10-year median of 205.48. Over the past 10 years, this metric has ranged from a low of 40.93 to a high of 302.42. The Drug Manufacturers industry median Days Payable is 90.22. Kangmei Pharmaceutical Co's value of 260.80 is 189.1% above this industry median. Based on the distribution chart, Kangmei Pharmaceutical Co ranks #120 out of 926 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Kangmei Pharmaceutical Co has a GF Score™ of 48/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Kangmei Pharmaceutical Co's Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Kangmei Pharmaceutical Co ranks #120 out of 926 companies for Days Payable. This places Kangmei Pharmaceutical Co in the top 13% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.22. Kangmei Pharmaceutical Co's value of 260.80 is 189.1% above this benchmark. Historically, Kangmei Pharmaceutical Co's own Days Payable has ranged from 40.93 to 302.42 over the past decade. While the company's 10-year median is 205.48 vs. the industry median of 90.22, Kangmei Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.22, based on 926 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kangmei Pharmaceutical Co's current Days Payable of 260.80 is 189.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Kangmei Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kangmei Pharmaceutical Co's current Days Payable is 260.80, which is 27% above median its own 10-year median of 205.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kangmei Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Kangmei Pharmaceutical Co (SHSE:600518) is currently considered Fairly Valued. The stock's GF Value™ is ¥1.46, compared to a current price of ¥1.35 — trading 7.5% below its estimated fair value. The current Days Payable is 260.80, which is 27% above median its 10-year median of 205.48 and 189.1% above the Drug Manufacturers industry median of 90.22. Kangmei Pharmaceutical Co's overall GF Score™ is 48/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Kangmei Pharmaceutical Co (SHSE:600518), the current Days Payable is 260.80 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kangmei Pharmaceutical Co (SHSE:600518) Overvalued in 2026?
Based on GuruFocus' analysis, Kangmei Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥1.35 is trading 7.5% below its estimated GF Value™ of ¥1.46.
GuruFocus considers Kangmei Pharmaceutical Co to be Fairly Valued.
Key valuation signals for SHSE:600518:
Days Payable: 260.80 (27% above median its 10-year median of 205.48)
GF Value™: ¥1.46 vs. price of ¥1.35 (7.5% below fair value)
Industry Position: 189.1% above the Drug Manufacturers median (#120 of 926)
No single metric tells the full story. See the SHSE:600518 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kangmei Pharmaceutical Co Ltd is a pharmaceutical company engaged in the trading of Chinese herbal medicines, production and sales of Chinese herbal medicine slices, Chinese patent medicine preparations, health foods, chemical drugs, and medical devices, modern pharmaceutical logistics system. The company is also engaged in medical equipment, property leasing and sales, and other services.
48GF Score
Get the complete analysis for SHSE:600518
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600518 has been successfully added to your 
